Regencell Bioscience (NASDAQ:RGC – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.01) earnings per share (EPS) for the quarter, FiscalAI reports.
Regencell Bioscience Trading Down 3.3%
Shares of RGC traded down $0.24 on Wednesday, reaching $7.11. The stock had a trading volume of 109,738 shares, compared to its average volume of 283,863. Regencell Bioscience has a 12-month low of $4.51 and a 12-month high of $69.00. The company has a 50-day simple moving average of $5.89 and a 200-day simple moving average of $15.07.
Analyst Upgrades and Downgrades
RGC has been the topic of a number of recent analyst reports. Wall Street Zen lowered Regencell Bioscience from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Monday, September 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.
Institutional Investors Weigh In On Regencell Bioscience
Hedge funds have recently bought and sold shares of the business. Seven Fleet Capital Management LP purchased a new stake in shares of Regencell Bioscience in the 4th quarter worth approximately $92,000. Amundi bought a new position in Regencell Bioscience in the first quarter valued at about $219,000. Finally, Bank of America Corp DE boosted its position in Regencell Bioscience by 59,113.8% in the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after purchasing an additional 17,143 shares during the last quarter. Institutional investors own 0.13% of the company’s stock.
About Regencell Bioscience
Regencell Bioscience Holdings Limited is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM) treatments for neurocognitive disorders and degenerative conditions. Its research has centered primarily on conditions such as dementia and attention-deficit/hyperactivity disorder (ADHD), with the goal of developing herbal formulations that may address underlying symptoms and disease-related challenges.
The company’s product development programs include proprietary TCM formulations intended for neurological and cognitive conditions.
See Also
- Five stocks we like better than Regencell Bioscience
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
- Morgan Stanley Is Bullish on Apple—But With a Catch
Receive News & Ratings for Regencell Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regencell Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
